This trial is evaluating whether Pembrolizumab will improve 3 primary outcomes and 5 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Through study completion, an average of 1 year.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"With regards to the term 'prostatistix’, there has been some controversy between the American Urology Association and the International Continence Society on one hand, and the Joint Committee on Tumor Markers and International Union Against Cancer on the other hand. The current definition recommends the use of Prostate-specific antigen (PSA) or a combination of prostate specific antigen with digital rectal examination and total PSA as a means of detection, which has been adopted by the Centers for Disease Control and Prevention (CDC) and as of April 2003 by the NWHH. A proposal for a revision is pending review by the International Continence Society and Joint Committee on Tumor Markers." - Anonymous Online Contributor
"At least 20 million people in the US are affected by prostate cancer at any one time. The incidence rate of prostate cancer in men ≥ 55 seems to be increasing and warrants further investigation." - Anonymous Online Contributor
"Prostate cancer cannot be cured. However some men, especially those with early-stage localized disease, can do well with treatment. Survival and quality of life can be improved dramatically with early treatment. It is important to discuss the issues of curability with patients at diagnosis." - Anonymous Online Contributor
"Factors that are believed to cause [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) are sexual dysfunction, diet, occupation, family history, an early age at start of regular intercourse, and a history of having a high-risk genotype for prostate cancer. Some of these factors are related to lifestyle factors and others are not. A high-fat diet is also suspected of increase the prostate cancer risk." - Anonymous Online Contributor
"Coughing, coughing fits, sneezing and chest discomfort are all suggestive of prostate cancer. There are five other important signs of prostate cancer. This includes unexplained rapid weight loss, unexplained genital pain or irritation, lower urinary tract symptoms, urinary retention, fever, or unintentional urine loss from the bladder (hematuria). People with those signs should be referred urgently to an urologist." - Anonymous Online Contributor
"Prostatitis is the most common benign cause of prostate symptoms in men. If symptoms persist after the treatment of the prostate cancer or when they are recurrent following treatment, the diagnosis of acute prostatitis should be considered. There are multiple treatment options including medical care alone or in combination with nonsteroidal anti-inflammatory drugs, such as ibuprofen. Antibiotics may be used together with NSAIDs to treat acute prostatitis. There are no single treatments considered to be the gold standard." - Anonymous Online Contributor
"In the randomized, phase III trial, pembrolizumab showed efficacy in preventing recurrence after radiotherapy in patients with post-prostatectomy progressive disease. Pembrolizumab did not shorten the overall survival duration after radical prostatectomy, nor did it decrease the radiotherapy doses required to achieve the optimal therapeutic ratio of radiation. However, the data obtained from the phase III study suggest a trend of efficacy in preventing second radiotherapy in the event of late progression and prolonging the overall survival duration; further studies are required to elucidate the possible effects of pembrolizumab in preventing the late progression of prostate cancer in patients with a positive surgical margin." - Anonymous Online Contributor
"Clinical trials for metastatic prostate cancer may benefit patients at all stages of clinical progression. Therefore, clinical trials should be considered as a treatment option for men with metastatic disease at diagnosis and for men with an indolent but progressive disease who do not respond to standard treatments, but the clinical benefit of such trials is still under assessment." - Anonymous Online Contributor
"This is the first study to evaluate the efficacy and safety profile of this anti-PD-1 therapy in patients with advanced cancer. In conclusion, the results showed a significant improvement in patients with metastatic prostate cancer, metastatic melanoma and head and neck cancer who were treated with pembrolizumab and metronomic platinum-based chemotherapy. In those patients who had progressive disease, a significant improvement in survival was also witnessed." - Anonymous Online Contributor
"From all prostate biopsies with > 5% cancer, only 37.7% showed local cancer spread (lymph node, distant metastasis) within the prostatic gland. Thus, prostate biopsy is insufficient to evaluate patients with a positive prostate cancer biopsy, especially if there are signs of local disease (lymph node or distant metastasis). The clinical relevance of this study should be further assessed by a prospective randomized study, comparing a more aggressive biopsy management with a less aggressive management in patients with prostate cancer diagnosed on prostate biopsy." - Anonymous Online Contributor
"It is found that a relatively small percentage of young men develop [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), however there are still concerns and discussions related to this and many other aspects of prostate health. Given the number of men in the United States annually treated for benign prostatic hypertrophy, these are major uncertainties with regard to patient education and prostate health management. Given these uncertainties, it is important for health professionals to be aware of these issues." - Anonymous Online Contributor
"It is suggested that in modern medicine, the [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) may be effectively treated only in some patients, using the following combination of treatments: an initial course of therapy on the basis of clinical and pathological examination; a course of radical prostatectomy; subsequent adjuvant therapy; periodic observation; no prophylactic treatment. After radical prostatectomy, it is advised to pay more attention to the patients' sexual function, quality of life and hormonal status than to the PSA level. It is advisable to have the possibility of performing a salvage prostatectomy if the PSA remains high or metastasizing disease is detected." - Anonymous Online Contributor